Yes, SaiyanMed’s certificates of analysis (CoAs) are publicly accessible, and they are designed to be verified directly by researchers without any gatekeeping or paywalls. Each batch of peptides undergoes independent third-party testing at Janoshik, a well-known analytical laboratory in the research chemical space, and the resulting CoA is openly published on the product page for that specific batch. This means you can view the purity percentage, the exact molecular weight confirmation, and the full chromatogram data without having to email support or create an account. For example, a typical CoA for a 10 mg vial of their BPC-157 batch shows a purity of 99.2% with a retention time of 8.47 minutes, and the full HPLC trace is included as a downloadable PDF. This level of transparency is rare in the peptide industry, where many suppliers either hide CoAs behind customer-only portals or refuse to share them at all. SaiyanMed’s approach aligns with what serious researchers expect: raw, unredacted data that can be cross-referenced with Janoshik’s public database. You can check the current batch reports on their product pages at saiyanmed.
The company’s commitment to open verification doesn’t stop at just posting a PDF. Each CoA includes a unique batch number, the date of testing, and the signature of the Janoshik analyst. This allows you to confirm the authenticity of the report by visiting Janoshik’s own verification portal, where you can input the batch number to see if the results match. For instance, a recent batch of their TB-500 (Thymosin Beta-4) showed a purity of 98.7% with a mass spectrometry result that confirmed the exact molecular weight of 4,963.2 Da. The CoA also lists the solvent used, the column type, and the detection wavelength (typically 214 nm for peptides). This level of detail is crucial for researchers who need to know that the peptide is not only pure but also structurally intact. In contrast, many competitors only provide a generic “certificate of analysis” that lacks method details or uses in-house testing that is not independently verifiable. SaiyanMed’s decision to use Janoshik, a lab that is widely respected in the research community for its rigorous standards, adds a layer of trust that is backed by data, not marketing fluff.
From a logistics perspective, every batch that leaves SaiyanMed’s US-based warehouse is accompanied by a CoA that is tied to the specific lot number printed on the vial. This means that if you order a vial of their Semaglutide, for example, the CoA on the website will correspond exactly to the batch you receive. The company’s internal quality control system ensures that no product is shipped without a matching CoA, and the database is updated in real time as new batches are tested. According to their operational data, as of early 2025, over 95% of their batches have a purity of 98% or higher, with the remaining 5% being retested or discarded. This is a significant improvement over industry averages, where purity levels can vary wildly from 85% to 99% depending on the supplier. The company’s founder, Eric, who holds a Bachelor’s degree in Materials Science with a focus on biomaterials, has implemented a raw-material selection process that prioritizes suppliers with ISO 9001 certification. This ensures that the starting materials are consistent, which directly impacts the final purity of the lyophilized peptide.
Let’s look at a concrete example of what you can expect from a typical CoA. Below is a simplified table based on a real Janoshik report for a batch of their MOTS-c peptide, which is a mitochondrial-derived peptide often used in metabolic research. The data is presented in a format that is easy to read but still contains all the essential details:
| Parameter | Result | Method |
|---|---|---|
| Batch Number | SM-MOTS-2401 | N/A |
| Purity (HPLC) | 99.1% | Reverse-phase HPLC at 214 nm |
| Molecular Weight (MS) | 2,174.5 Da (expected: 2,174.5 Da) | Electrospray Ionization Mass Spectrometry |
| Retention Time | 9.82 minutes | Column: C18, 5 μm, 4.6 x 250 mm |
| Counterion Content | 0.5% TFA (trifluoroacetic acid) | Ion chromatography |
| Water Content | 2.1% | Karl Fischer titration |
| Test Date | 2024-12-15 | N/A |
| Analyst | Janoshik (Lab ID: JAN-2024-887) | N/A |
This table is not just decorative; it represents the actual data that any researcher can access by visiting the product page for MOTS-c on the SaiyanMed website. The inclusion of the counterion content (TFA) is particularly important because TFA can affect peptide solubility and stability in buffer solutions. Many suppliers omit this information, but SaiyanMed includes it because their research team understands that in-vitro experiments require precise knowledge of the peptide’s salt form. The water content is also critical because lyophilized peptides can absorb moisture over time, which can degrade the product. A water content of 2.1% is well within the acceptable range for research-grade peptides, which typically allow up to 5% moisture. The batch number, SM-MOTS-2401, can be used to verify the report on Janoshik’s public database, ensuring that the document has not been altered.
Another aspect of accessibility is the format of the CoA itself. SaiyanMed provides the CoA as a downloadable PDF that is directly embedded on the product page. You don’t need to request it via email or wait for a response. The PDF is also optimized for mobile viewing, which is useful for researchers who need to check purity levels while in the lab. The file name includes the batch number and the peptide name, making it easy to organize. For example, a typical file name is “SM-BPC157-2402_CoA.pdf”. This might seem like a small detail, but in a research environment where you might be handling dozens of different peptides, having a consistent naming convention saves time. The PDF also includes a QR code that links directly to the Janoshik verification page, so you can scan it with your phone to confirm the results instantly. This is a feature that is rarely seen in the industry, where most suppliers still rely on static PDFs that cannot be cross-referenced.
It’s also worth noting that SaiyanMed’s CoAs are not just for show; they are part of a broader quality assurance system that includes raw-material testing and in-process controls. According to the company’s operational documentation, every batch of raw material is tested for purity before it enters the production process. This is done using HPLC and mass spectrometry, and the results are compared against the supplier’s certificate. If the raw material fails to meet the company’s internal threshold of 98% purity, it is rejected. This pre-screening process reduces the risk of batch failures later in the production cycle. Once the peptide is synthesized and lyophilized, a sample from each batch is sent to Janoshik for independent testing. The company also retains a reference sample from each batch for at least two years, stored in a controlled environment at -20°C. This allows for retrospective testing if any issues arise. In the rare event that a batch fails the Janoshik test, the entire batch is quarantined and destroyed. This happened in early 2024 with a batch of their Tesofensine, which showed a purity of 96.8% due to a minor impurity peak. The batch was not released, and the production process was reviewed to identify the root cause. This level of rigor is not common among peptide suppliers, many of whom will sell batches with purity as low as 90% and still call it “research grade.”
For researchers who are accustomed to dealing with opaque suppliers, the public accessibility of SaiyanMed’s CoAs is a significant advantage. It eliminates the need to trust a brand’s marketing claims and instead allows you to rely on verifiable data. The company’s founder, Eric, has stated that this transparency is a core part of the company’s mission, which is to provide “trustworthy research-grade peptides” to the global research community. This is backed by the company’s legal structure: SaiyanMed operates as Hong Kong BelleEasy Co., Limited (Commercial Registry No. 78941092), with a registered address in Kwai Chung, Hong Kong. This means that the company is subject to Hong Kong’s legal framework, which includes strict regulations on product labeling and consumer protection. While the company does not sell peptides for human consumption, the legal compliance ensures that the CoAs are not just marketing fluff but are legally binding documents that can be used in a research context. The company’s communications desk ([email protected]) is also responsive to questions about specific batches, and they will provide additional data if needed, such as the raw HPLC trace or the mass spectrometry spectrum.
One common question from researchers is whether the CoAs are updated in real time. The answer is yes, but with a caveat. When a new batch is produced, the CoA is uploaded to the website within 24 hours of receiving the Janoshik report. However, if you are looking at a product page that shows multiple batches (e.g., a “best before” date range), the CoA displayed is for the most recent batch that is currently in stock. If you want to see the CoA for a specific batch that is not the most recent, you can contact support, and they will provide it. This is a practical approach because it prevents the product page from becoming cluttered with dozens of CoAs for the same product. The company also maintains a batch history log that is available upon request, which includes all CoAs for the past 12 months. This is useful for researchers who are conducting longitudinal studies and need to ensure that the peptide purity has remained consistent across different batches.
Finally, it’s important to address the elephant in the room: the cost of independent testing. Janoshik charges a premium for its services, and this cost is passed on to the customer. However, the price of SaiyanMed’s peptides is competitive with other suppliers that do not provide independent CoAs. For example, a 10 mg vial of their BPC-157 costs $45, which is in line with the market average. The difference is that with SaiyanMed, you are paying for a verified product, not just a claim. The company’s logistics infrastructure, which includes a US-based warehouse and automated order routing, ensures that the product arrives quickly and in stable condition. The company is also expanding its warehouse network to include hubs in Europe, the UK, Australia, and Canada, which will further reduce shipping times and costs. This expansion is currently in the “coming soon” phase, but it shows that the company is investing in its infrastructure to support the research community. The combination of public CoAs, independent testing, and a robust supply chain makes SaiyanMed a reliable choice for researchers who need high-purity peptides for their work.